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ABSTRACT
Triplex-formingoligonucleotides(TFOs)arepowerful
tools to interfere sequence-specifically with DNA-
associated biological functions. (A/T,G)-containing
TFOs are more commonly used in cells than (T,C)-
containing TFOs, especially C-rich sequences;
indeed the low intracellular stability of the non-
covalent pyrimidine triplexes make the latter less
active. In this work we studied the possibility to
enhance DNA binding of (T,C)-containing TFOs, aim-
ing to reach cellular activities; to this end, we used
locked nucleic acid-modified TFOs (TFO/LNAs) in
association with 50-conjugation of an intercalating
agent, an acridine derivative. In vitro a stable triplex
was formed with the TFO-acridine conjugate: by
SPR measurements at 37 C and neutral pH, the
dissociation equilibrium constant was found in the
nanomolar range and the triplex half-life  10 h (50-
fold longer compared with the unconjugated TFO/
LNA). Moreover to further understand DNA binding
of (T,C)-containing TFO/LNAs, hybridization studies
were performed at different pH values: triplex stabil-
izationassociatedwithpHdecreasewasmainlydueto
a slower dissociation process. Finally, biological
activity of pyrimidine TFO/LNAs was evaluated in
a cellular context: it occurred at concentrations
 0.1 mM for acridine-conjugated TFO/LNA (or
 2 mM for the unconjugated TFO/LNA) whereas the
corresponding phosphodiester TFO was inactive,
and it was demonstrated to be triplex-mediated.
INTRODUCTION
Molecules able to speciﬁcally recognize predetermined
sequences in the DNA double helix are appropriate to modu-
late DNA-associated biological functions. Triplex-forming
oligonucleotides (TFOs) bind in the major groove of oligopyr-
imidine oligopurine sequences allowing speciﬁc targeting of
the double-stranded DNA. The TFO can form Hoogsteen or
reverse Hoogsteen hydrogen bonds with the purine-containing
strand of the double helix, depending on the nature of the
target sequence. Structural requirements inﬂuence the design
of TFOs and has lead to the classiﬁcation in different subtypes
with individual binding properties (1). TFOs containing C and
T nucleotides (also named pyrimidine TFOs) bind in parallel
orientation via Hoogsteen hydrogen bonds [(T,C)-motif] and
their binding decreased at physiological pH since cytosines
must be protonated to support a second hydrogen bond; TFOs
containingGandAorTnucleotides[(G,A)-and(G,T)-motifs]
bind mainly in anti-parallel orientation via reverse Hoogsteen
bonds and their binding is disfavored by intracellular concen-
tration of potassium since they can be involved in auto-
association processes that could compete with triplex forma-
tion and induce additional interactions with speciﬁc proteins,
leading to side effects in cells. However, TFOs have been
successfully used as DNA code-reading molecules in vitro
and in cells, and triplex formation has been demonstrated
to interfere in a sequence-speciﬁc manner with biological
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doi:10.1093/nar/gki726functions occurring on DNA, namely transcription (initiation
and elongation), replication, repair and recombination, and has
also been useful to guide molecules acting on DNA unspeciﬁ-
cally, such as DNA damaging agents [for reviews see (2,3)].
For all triplex-based applications in cells, pyrimidine TFOs,
especially C-rich sequences, have been demonstrated to be
only weakly active, and G-containing TFOs are therefore
the mostcommonlyusedTFOs. Yeta remainingkey challenge
to be addressed is the current low efﬁciency of TFO-induced
activities in cells. One approach consists in improvement of
the ability of TFOs to form a stable complex in a cellular
context. To reach this goal, many efforts have been focused
on developing chemically modiﬁed oligonucleotides. Among
them, locked nucleic acids (LNA) that contain ribonucleotides
with a 20-O,40-C-methylene linkage have been synthesized as
described previously (4,5). LNA-containing TFOs have been
recently described to effect very signiﬁcant triplex stabiliza-
tion. Previous works have thus shown that alternating LNA
and DNA nucleotides in TFO sequences is appropriate for
triplex formation (6,7). In this context, in vitro favorable bind-
ing properties of pyrimidine LNA-modiﬁed TFOs (TFO/
LNAs) have been reported, providing evidence that LNA-
induced triplex stabilization compared to the non-modiﬁed
TFO is associated with a reduced entropic barrier (most proba-
bly due to appropriate preorganization of the TFO/LNA) and a
slower dissociation rate constant (8). To date, pyrimidine
TFO/LNAs have been used only for in vitro applications
(9). Still, LNA-modiﬁed oligonucleotides are promising mole-
cules,evenforinvivoapplications, assupportedbytheir useas
antisense agents (10,11). Alternatively, TFO-intercalator con-
jugates have been synthesized. The most commonly used
intercalators are acridine (Acr) and psoralen (Pso) derivatives,
the latter being mainly used in association with irradiation,
as a photoactive DNA cross-linker. It is established that
they stabilize the triplex when attached at the end of the
TFO, most probably by preferential intercalation at the
duplex–triplex junction (12). In fact, a few hybridization stud-
ies of such conjugates have been reported so far. It has been
shownthatthetriplexstabilizationinducedbytheintercalating
agent can be observed in different contexts, such as different
TFO chemistries (phosphodiester, phosphorotioate, phos-
phoramidate, 20-O-methyl sugars) as well as different TFO
binding motifs [(T, C)-, (T, G)- or (A, G)-containing TFOs]
(13–15). Furthermore, either the 50 or the 30 end of TFOs can
be conjugated with appropriate linkers attached to intercalator
(16). Using this approach, increase in triplex stability has been
described, but only using gel shift assays (for determination of
the concentration necessary for 50% triplex formation) or UV
melting experiments (for determination of melting tempera-
ture, Tm). In cellular applications, intercalating agents have
beenattachedtoTFOs (phosphodiester andbackboneorsugar-
modiﬁed) and the corresponding conjugates have been shown
to exhibit biological activity (17–19).
Inthe present work the objectives are toevaluate the triplex-
forming properties and intracellular activities of pyrimidine
TFO/LNAs conjugated or not to an acridine derivative, used
as a model of a DNA intercalating agent. We have for the
ﬁrst time characterized the kinetic origins of triplex stabiliza-
tion induced by acridine conjugation. The pH-dependence of
pyrimidine TFO/LNA binding was also explored. To study
these aspects, surface plasmon resonance (SPR) biosensor
technology was used to evaluate kinetic parameters of triplex
formation. Finally, we determined the ability of the TFO/
LNAs to interfere with DNA acting proteins in vitro and in
cells, and we used experimental systems designed to demon-
strateatriplex-basedmechanismandtoevaluate theadvantage
of pyrimidine TFO/LNAs. We provide evidence of biological
activities of pyrimidine TFO/LNAs in a cellular context, as
monitored by inhibition of transcription elongation, under
conditions where the parent phosphodiester TFOs were inac-
tive. The TFO/LNA-acridine conjugate was active at submi-
cromolar concentrations ( 0.1 mM) and the unconjugated
TFO/LNA in the micromolar range ( 2 mM); to our
knowledge, such efﬁciency in cellular triplex-based activities
has never been reported previously for any pyrimidine
C-rich TFO. Our results encourage further developments of
TFO/LNAs to interfere with DNA metabolism.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotide analogues with LNA residues were synthe-
sized as described previously (4) or purchased from Proligo
(France SAS). For cellular experiments, the phosphodiester
oligonucleotide (Acr-16TC/po, sequence in Figure 1) was 30-
modiﬁed by incorporation of a propylamine group (named
Acr-16TC
$/po) to resist nuclease-mediated degradation.
The covalent attachment of acridine to the 50 end of 16TC/
LNA and 16py(2)/LNA TFOs was achieved by the reaction
of 2-methoxy-6-chloro-9-(w-bromohexylamino)-acridine (20)
with 50-thiophosphorylated 16TC/LNA and 16py(2)/LNA
sequences (purchased from Proligo) by a method adapted
from a previously reported procedure (21). Lyophilized
ODNs (sp-16TC/LNA or sp-16py(2)/LNA) (20 OD units)
were dissolved in MeOH (1 ml) in the presence of
A
PPT 5 TTTAAAAGAAAAGGGGGGA 3
3 AAATTTTCTTTTCCCCCCT 5
mutPPT  5 AAAAGAAAAAGGAGGA 3
3 TTTTCTTTTTCCTCCT 5
B
5-tTtTcTtTt 9TC/LNA
  5-tTtT cTtTtCcCcCc t 16TC/LNA
  5-tTcctTCtCtCTcTct 16py(1)/LNA
 Acridine -(5)- tTtTcTtTt CcCcCc t Acr-16TC/LNA
 Acridine -(5)- TTTTCTTTT CCCCCC T Acr-16TC/po
 Acridine -(5)- tTtTTtT ctCcCtCcc Acr-16py(2)/LNA
 Psoralen -(5)- tTtTcTtTt CcCcCc t Pso-16TC/LNA
Figure 1. Sequences of the oligopyrimidine oligopurine DNA targets (A) and
of the oligonucleotides (B) used in this study. (A) The wild-type PPT target
sequence (boxed), Dra I recognition site (underlined) are shown, as well as the
mutated PPT duplex presenting two mutations (in bold). (B) (T,C)-containing
TFOs directed against the wild-type PPT duplex and control sequences. Small
letters indicate LNA nucleotides and capitals DNA nucleotides. Cytosines
in italic (C and c) are methylated at position 5; all cytosines (LNA and
DNA) are 5-methylated. The abbreviated names are indicated near the
sequences. (po) stands for phosphodiester. Last four TFOs are either acridine
(Acr) or psoralen (Pso) 50-conjugated TFO/LNAs.
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(0.002 g) dissolved in MeOH (0.5 ml) was added. The mixture
was incubated with stirring at room temperature for 24 h and
then concentrated to dryness. 1 M sodium phosphate buffer
(1 ml), pH 6, was added and the excess of acridine derivative
was extracted from CH2Cl2 (3 · 3 ml). The crude conjugates
were puriﬁed by reversed-phase chromatography using a
Licrhospher 100 RP 18 (5 mm) column (12.5 · 4m m
2;
Merck) and a linear gradient of CH3CN (5–35% in 40 min)
in 0.1 M TEAA, pH 7, buffer with a ﬂow rate of 1 ml/min.
Conjugates were eluted with retention times 10 min longer
than those of the corresponding 50-thiophosphorylated TFOs.
The conjugates Acr-16TC/LNA and Acr-16py(2)/LNA were
characterized by UV absorption spectroscopy and electro-
spray mass spectrometry analysis. Acr-16TC/LNA: Found:
5485.81 ± 0.77 (calculated: 5487.27 for C189H238ClN41
O115P16S). Acr-16py (2)/LNA: Found: 5485.79 ± 0.94 (calcu-
lated: 5487.27 for C189H238ClN41O115P16S).
Plasmids
The pSP-F47 plasmid was constructed by insertion of a 780 bp
fragment of the HIV-1/nef gene containing the oligopyrimi-
dine oligopurine PPT target sequence, between the T7 and SP6
promoters, in the pSP73 host vector (Promega), as previously
described in details (22). This system allows to run bidirec-
tional in vitro transcription assays.
The (+)PPT/luc and (+)mutPPT/luc plasmids contain the
ﬁreﬂy luciferase (Photinus pyralis) under the control of the
murine phosphoglycerate kinase (PGK) promoter. A 34 bp
insert [50-CCACTTTTT(PPT or mutPPT)CTGGAAGGG-30]
containing the wild-type HIV-1 oligopurine tract (PPT:
50-AAAAGAAAAGGGGGGA-30) or a mutated version
(mutPPT: 50-AAAAGAAAAAGGAGGA-30, 2 mutations in
bold) was cloned on the 50-transcribed sequence of the
luciferase gene in the (+)PPT/luc or (+)mutPPT/luc, 113 bp
downstream of the PGK start site. These constructs have been
described in more details (15).
The pRL-TK vector (Promega) contains the Renilla
luciferase (RL, from the marine organism Renilla reniformis)
under the control of the TK promoter. pRL-TK was used to
monitor transfection efﬁciency.
Electrophoresis mobility shift assay
PPT or mutPPT hairpin intramolecular duplexes were 50 end-
labeled with [g-
32P]ATP (3000 Ci/mmol, Amersham Pharma-
cia Biotech.) by T4 polynucleotide kinase (Promega). The
duplex (2 nM) was incubated with increasing concentrations
of TFO in a buffer containing 50 mM HEPES pH 7.2, 150 mM
NaCl, 1 mM MgCl2, 0.5 mM spermine, 0.1 mg shared salmon
sperm DNA and 10% sucrose. The non-denaturing polyacry-
lamidegel(15%)wasrunat37 Cinabuffercontaining50mM
HEPES pH 7.2 and 1 mM MgCl2. Gels were scanned
with phosphorimager and results quantiﬁed (±5%) using the
Image-Quant software (Molecular Dynamics). The level of
complex formation was estimated by the TFO concentration
where 50% of the complex was formed (C50).
UV absorption melting experiments
All thermal denaturation experiments were performed in a
10 mM sodium cacodylate buffer (at the indicated pH
value) containing either 10 mM MgCl2 and 150 mM NaCl,
or 100 mM NaCl. The sample contained 1 mM duplex (PPT or
mutPPT duplex: 29 bp long intramolecular hairpin duplexes)
and 1.5 mM TFO (see sequences in Figure 1). Melting
proﬁles were recorded at 260 nm, using an UVIKON 940
spectrophometer, as already described (23). Corrections for
spectrophotometric instability were made by subtracting the
absorbance at 405 nm from that at 260 nm. The temperature
was decreased from 92 to 0 C and increased again to 92 Ca ta
rate of 0.2 C/min. All the cooling and heating proﬁles pre-
sented here were reversible except in the case presented in
FigureS1. The melting temperature(Tmin  C) was determined
from melting curves, both directly and after subtraction of the
duplex absorption from that of the triplex. The triplex Tm was
estimated within (±) 0.5 C accuracy, except when the melting
proﬁles of triplex transition presented a hysteresis [(±)1.5 C
accuracy in Tm].
SPR experiments
SPR measurements were performed on a BIAcore 2000 
(BIAcore AB, Sweden) using a carboxymethylated dextran-
coated sensor chip (CM5), as previously described (24).
Brieﬂy, one micromolar solutions of 30-biotinylated hairpin
duplexes (PPT duplex and control duplex 50-GCTAAAGA-
GAGAGAGAAATCGTTTTCGATTCTCTCTCTCTTTAGC-
TTTTTT-Biotin) were prepared in a buffer containing 10 mM
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.0005%
surfactant P20; purchased by BIAcore) and duplex injection
was controlled to obtain a 1500 RU increase. Serial dilutions
of TFO were prepared in 10 mM sodium cacodylate, with
either 10 mM MgCl2, 150 mM NaCl, or 100 mM NaCl,
and 0.0005% surfactant P20 at pH 6.5 or 7. These triplex-
forming buffer conditions are the same as the ones used in UV
absorption melting experiments. Serial TFO injections were
performedsimultaneouslyonthehairpinduplexcontainingthe
target PPT sequence and on the control duplexlacking the PPT
sequence. All the sensor grams were corrected by subtraction
of the control duplex signal, reﬂecting mainly bulk index
changes. A typical sensor gram was shown in Figure S2.
The sonograms were analyzed using the BIAevaluation 3.0
software. The association rate constant kon was determined
by the linear ﬁtting of the apparent association rate constant
[kapp ¼ kon · (TFO) + koff] at different TFO concentrations, in
agreement with a two-state model; for kon, experimental error
was (±) 15%. Noteworthy, concerning the dissociation pro-
cess,forthe acridine-conjugatedTFO/LNA(Acr-16TC/LNA),
it was very slow under our experimental conditions and
koff values were likely overestimated since the dissociation
half-life of the triplex was long compared to the analysis
time ( 2 h). The mass transport effects were negligible
under our experimental conditions.
Restriction enzyme (Dra I) protection assay
The pCMV(+)PPT/luc plasmid contains the PPT sequence
overlapping one of the 7 Dra I sites [for detailed description,
see (25)]. It was used as a substrate for a restriction enzyme
protectionassay.Forthe cleavage assay,the pCMV(+)PPT/luc
plasmid was incubated at 37 C for 20 min, with increasing
amounts of oligonucleotides in 50 mM HEPES pH 7.2, 50 mM
NaCl, 10 mM MgCl2 and 0.5 mM spermine in the presence of
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absence of TFO are 1936, 1718, 692, 683, 534 and 19 bp long.
A 3654 bp fragment corresponding to the addition of the 1936
and the1718 bp fragments was obtained when TFO-induced
inhibition of Dra I cleavage occured. The extent of triplex-
mediated inhibition of Dra I cleavage was assessed by gel
electrophoresis (0.8% agarose gel) and quantiﬁed (with an
estimated error of (±) 5%). The TFO concentration giving
50% inhibition (IC50) was then evaluated.
In vitro transcription assay
Transcription assays were performed using the pSP-F47
plasmid that contains the PPT sequence between T7 and
SP6 promoters. The plasmid was linearized by BspE 1 for T7
transcription and synthesis of purine/PPT-containing RNA
(660 nt long), or by Bsu36 I for synthesis of pyrimidine/
PPT-containing RNA (597 nt long). The linearized plamids
(0.5 mg) were used for in vitro transcription assays in the
presenceofincreasingamountsofTFOs, inabuffercontaining
40 mM Tris–HCl, pH 7.2, 6 mM MgCl2, 2 mM spermidine,
4 mM DTT, 1 U/ml RNase inhibitor in presence of 500 mM
ATP, CTP and UTP, 100 mM GTP and 0.3 mM[ a-
32P]GTP.
Transcription was initiated by addition of 25 U of phage RNA
polymerase (T7 or SP6). After 5 min at 37 C, transcription
reactions were terminated by ethanol precipitation (10 vol
ethanol added to samples with 0.3 M sodium acetate and
15 mg glycogen). The transcription products were analyzed
by electrophoresis on 6% polyacrylamide gels and quantiﬁca-
tions (±10%) obtained by phosphorimager analysis. The per-
centages were corrected for transcript length effects taking
into account that the transcripts were uniformly radiolabeled.
Cell cultures and transient expression assay
The P4-CCR5 cells were derived from HeLa cells (26) and
maintained in DMEM supplemented with 10% fetal bovine
serum.
P4-CCR5 cells were used for transfection of oligonu-
cleotides and reporter vectors. Transfections were performed
using the cationic activated dendrimer Superfect (Quiagen).
Typically two mixtures were prepared in parallel: the plasmid
containing mixture and the oligonucleotide containing one. In
the plasmid mixture, 0.1 mgo f( +)PPT/luc [or (+)mutPPT/luc]
plasmid and 0.05 mg pRL-TK plasmid were mixed with 0.9 ml
Superfect in 7.2 ml of serum-free medium, and in the oligonu-
cleotide mixture, various amounts of oligonucleotides were
mixed with 0.6 ml Superfect in 4.8 ml of serum-free medium.
The two mixtures were prepared for triplicates and they were
added to P4-CCR5 cells (13750 cells per well in 96-well
plate in 90 ml of serum-containing medium) at the same
time; we also carried out sequential transfections separated
by 24 h the oligonucleotide mixture was transfected ﬁrst,
and 24 h later the cells were washed before transfection of
the plasmid mixture.In both cases, cells were lysed (in 30 mlof
Passive Lysis Buffer, Promega) and activities of both
luciferases (ﬁreﬂy and Renilla) were measured in the same
cell extract using the dual-luciferase assay kit (Promega).
Luciferase expressions were measured with a luminometer
(Victor -Wallac). The modulation of ﬁreﬂy luciferase
expression by oligonucleotide treatment was quantiﬁed by
evaluation of the ratio ﬁreﬂy/Renilla. Each experiment was
repeated at least three times and values were presented as the
mean of a triplicate (±SD) from a representative experiment.
RNA analysis
Total cellular RNA were prepared from extraction of 27500
cells with the RNeasy Mini kit (Qiagen). Fireﬂy and Renilla
luciferase RNAs were subjected to competitive RT–PCR [for
details from cDNA, see (27)]. Brieﬂy two sets of two PCR
primers were designed for each luciferase RNA; two competi-
tors DNA (ﬁreﬂy and Renilla) were used and co-ampliﬁed
with the RNA sample. The sequences of the primers were
the following ones: for ﬁreﬂy, 50 GCT GTT CTC CTC
TTC CTC AT and 50 CAG GGC GTA TCT CTT CAT
AG; for Renilla 50 GCG ACA TGT TGT GCC ACA TA
and 50 ATC AGG CCA TTC ATC CCA TG. Conditions
for PCR were 10 min at 95 C, 35 cycles (1 min at 94 C;
30 s at 57 C, 30 s at 72 C), 10 min at 72 C.
For each luciferase, the two ampliﬁed products (from
sample tocompetitorwhich are 210 and176 bp longforﬁreﬂy,
and 250 and 294 bp long for Renilla, respectively) were sepa-
rated using an 8% PAGE in TBE, and the level of RNA was
quantiﬁed by Phosphorimager analysis after successive
dilutions.
RESULTS
Strong and specific binding of intercalator conjugates of
pyrimidine TFO/LNAs at physiological pH: defining
its molecular basis
In this work we have studied the binding and biological prop-
erties of pyrimidine TFO/LNAs attached or not to a DNA
intercalating agent. In the majority of experiments we used
TFOs conjugated to an acridine derivative, the 2-methoxy-6-
chloro-9-amino-acridine (Acr), known to intercalate in DNA,
paralleltothebasepairs.Theacridine wasattachedviaalinker
of six carbons to the 50-end of TFO/LNAs (Figure 1), as it was
already done for other TFO chemistries, namely phosphodi-
ester, phosphoramidates or phosphorothioates (14,15,22).
LNA modiﬁcations were introduced alternatively in the
sequence of (T,C)-containing TFOs, since fully modiﬁed
TFO/LNAs failed to bind to double-stranded DNA (7). As
a target we chose a 16 bp long oligopyrimidine·oligopurine
sequence (named PPT duplex).
Stability and speciﬁcity of triplexes formed by the (T,C)-
containing TFO/LNAs (Acr-16TC/LNA and 16TC/LNA) and
the PPT target sequence, were ﬁrst evaluated by gel shift
experiments (Figure 2; Materials and Methods). TFO concen-
tration required for 50% of complex formation (C50) was
estimated. Under these conditions simulating physiological
ones, complex formation with the acridine-conjugated 16TC/
LNA was detected in the nanomolar range [C50(Acr-16TC/
LNA) ¼ 5–10 nM]. In order to estimate the inﬂuence of acri-
dine conjugation on triplex formation, the binding of uncon-
jugated 16TC/LNA to the PPT duplex was assessed under the
same conditions, and 50% triplex formation was seen at
100 nM concentration. Quantiﬁcations of the retarded band,
reﬂecting complex formation, was reported for various TFO
concentrations (Figure 2B). In the presence of Acr-16TC/
LNA, 90% of complex was formed at a concentration as
low as 25 nM, whereas 250 nM of unconjugated 16TC/
4226 Nucleic Acids Research, 2005, Vol. 33, No. 13LNA was required for equivalent binding. It is noticeable that
under these conditions the isosequential Acr-16TC/po was
unable to form a complex with the PPT target up to 10 mM,
consistent with high LNA-induced stabilization, as already
described for other LNA-modiﬁed TFOs (8).
In orderto assess the speciﬁcityof duplex recognition bythe
16TC/LNA, conjugated or not to the acridine unit, we com-
paredtheir binding to the PPT duplex target and to the mutPPT
duplex containing two mutations in the triplex site (50 AAAA-
GAAAAAGGAGGA-30, mutations in bold). For the unconju-
gated 16TC/LNA, no binding was detected up to 2 mM (at this
concentration the complex was completely formed on PPT
duplex). For the Acr-16TC/LNA, a 5-fold increase in C50
was obtained compared to the wild-type sequence [C50
(Acr-16TC/LNA; mutPPT) ¼ 25 nM]. These data on binding
selectivity [for 16TC/LNA, C50(mutPPT)/C50(PPT) > 20 and
for Acr-16TC/LNA, C50(mutPPT)/C50(PPT) ¼ 5] must be
commented taking into account the facts that: (i) nine con-
tiguous triplets could theoretically be formed with the A4GA4
sequence on both of the two targets (PPT and mutPPT); (ii) in
our experimental conditions (neutral pH) the binding was
mainly driven by the T-rich part of the 16TC sequence (50-
TTTCTTTT; as it will be shown later); (iii) this T-rich part is
attached toacridine inAcr-16TC/LNA. Thus inthe Acr-16TC/
LNA, acridine intercalation should stabilize the formation of
the nine base triplets to the mutPPT duplex and prevent
dissociation during gel analysis when compared to the
16TC/LNA. Indeed with the mutPPT duplex the migration
of the retarded band (T) was reduced compared to that
observed with the PPT duplex (T), consistent with a less com-
pact structure that might correspond to a partial binding of the
Acr-16TC/LNA.
To further quantify the binding to DNA of pyrimidine TFO/
LNAs and the inﬂuence of acridine conjugation, UV absorp-
tion melting experiments were carried out (Table 1).
As expected, the presence of the intercalating agent at the
50-end of the 16TC/LNA strongly increases the triplex-
forming ability of the oligomers compared to the unconjugated
16TC/LNA.Thusa 10 Cincreaseinthemeltingtemperature
was observed compared to the corresponding pyrimidine
sequence 16TC/LNA [Tm(Acr-16TC/LNA) ¼ 41 C and
Tm(16TC/LNA)  29.5 C]. As expected the presence of LNA
modiﬁcations results in a strong increase in Tm compared to
the isosequential phosphodiester TFOs conjugated or not to
acridine (Acr-16TC/po, 16/TC/po). These data on acridine-
induced stabilization of TFO/LNAs are consistent with
those obtained with other TFO chemistries.
The binding speciﬁcity of the Acr-16TC/LNA was evalu-
ated, using the mutPPT duplex as a target like in gel shift
assays. We showed that Acr-16TC/LNA could discriminate
between the wild-type and the mutated target with a large
(µ µM)
(µM)
TFO concentration (µM)
Figure 2. Triplex formation with (T,C)-containing TFO/LNAs: gel shift assays. (A) Increasing concentrations of 16TC/LNA or Acr-16TC/LNA were incubated in
150mMsodiumchloride,50mMHEPESpH7.2,1mMMgCl2and0.5mMspermine,eitherwithPPT(left)ormutPPT(right)duplex.Thesampleswereanalysedby
electrophoresisin15%non-denaturingpolyacrylamidegel(50mMHEPES,pH7.2,1mMMgCl2)at37  C.D:duplex;(T,T0):triplex.(B)Quantificationofretarded
band reflecting complex formation between 16TC/LNA (filled or open diamonds) or Acr-16TC/LNA (filled or open circles) and PPT or mutPPT duplex (filled or
open symbols, respectively). C50 values corresponding to TFO concentrations for 50% triplex formation were estimated from these gel shift quantifications.
Table 1. Melting temperatures (Tm values) of the different (T,C)-containing
TFOswiththePPTormutPPTtargetduplex(indicatedinbrackets)indifferent
buffer conditions
TFO pH Buffer Tm( C)
Target: PPTduplex
(mutPPT duplex)
Acr-16TC/LNA 7.0 L 41 (31)
16TC/LNA 7.0 L 29.5
a(n.d)
Acr-16TC/LNA 7.0 H n.d.
16TC/LNA 7.0 H 37 (34)
9TC/LNA 7.0 H 37 (37)
16TC/LNA 6.5 H 47 (38)
9TC/LNA 6.5 H 42 (42)
16TC/po 6.5 H 10
b
16TC/LNA 6.0 H 56
9TC/LNA 6.0 H 46 (45)
Acr-16TC/po 6.0 H 35 (30)
16TC/po 6.0 H 18
The data were obtained in a buffer containing 10 mM cacodylate, 150 mM
sodium chloride, 10 mM MgCl2 (Buffer H) or in 10 mM cacodylate, 100 mM
sodium chloride (Buffer L). Strand concentrations: 1 mM PPT duplex and 1.5
mMTFO.Specificconditionsareindicated.EstimatederrorsinTm(±)0.5 C,or
(±) 1.5 C for cases indicated with (
a and
b), which correspond to a triplex
transition with a hysteresis phenomenon between cooling and heating profiles
(Figure S1) or with a melting profile lacking a complete base line at low
temperatures, respectively. (n.d.): not determined, either because the triplex
and duplex transitions were superimposed or the triplex transition presented a
weak hyperchromic change and a hysteresis profile.
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Table 1]. This was also the case for the 16TC/LNA.
These results obtained with Acr-16TC/LNAs in two differ-
ent experimental settings show the formation of a highly stable
complex with the Acr-16TC/LNA under conditions closely
mimicking physiological ones, and demonstrate a strong
increase in thermal stability induced by conjugation of an
intercalator still allowing speciﬁc binding of acridine-
conjugated TFO/LNA to the PPT duplex target.
To investigate the origin of the high stability of triplexes
formed with TFO/LNA-intercalator conjugates, we performed
kinetic analyses using SPR experiments with the Acr-16TC/
LNA and the 16TC/LNA (Table 2).
Compared to the unconjugated 16TC/LNA, triplex forma-
tion with the conjugate exhibited a slightly faster ( 3-fold)
association rate and a much slower dissociation ( 50-fold
decrease in koff). These kinetic data demonstrate that the sig-
niﬁcant stabilization observed for triplexes formed with the
TFO/LNA-intercalator conjugates [Kd (37 C; Acr-16TC/
LNA)  8.4 nM; Kd (37 C; 16TC/LNA) ¼ 1.7 mM;
Figure 3] are mainly due to a longer lifetime [t ¼ (ln2/koff)
in the range of  10 h at 37 C compared to  7.5 min for the
unconjugated TFO/LNA] and to a lesser extent, to a faster
association (3-fold increase compared to the unconjugated
16TC/LNA).
pH-dependence of pyrimidine TFO/LNA binding
The pH-induced effects on triplexes formed with pyrimidine
TFO/LNAs were studied using UV absorption melting
(Figure 4, Table 1) and SPR experiments (Table 2).
Two different pyrimidine TFO/LNAs were studied (16TC/
LNA and 9TC/LNA), all composed of alternating LNA and
DNA nucleotides along the sequence, with all cytosines being
methylated (Figure 1). The shorter TFO (9TC/LNA) is a trun-
cated version of the 16TC/LNA, lacking the C-rich sequence
(CCCCCCT-30) and is used to evaluate, as a function of the pH
value, the binding of the C-rich part of the 16TC sequences
by comparison with the 16TC/LNA.
We ﬁrst examined the thermal stability of triplexes formed
with the different (T,C)-containing TFO/LNAs at different
pH values and compared to results obtained with phosphodi-
ester TFOs. Since Acr-16TC/LNA exhibited high Tm value at
pH value as high as 7 it was excluded from the study, but
the pH-dependence of triplex formation is likely governed
by the oligonucleotide part of the conjugate and results
obtained with the 16TC/LNA may be valid also for the
Acr-16TC/LNA.
Table 2. Kinetics of triplexes formed with different TFO/LNAs: kinetic rate constants koff and kon and the corresponding calculated equilibrium constants
Kd ¼ (koff/kon)
TFO T( C) pH kon(M
 1s
 1) kon(s
 1) t(s) ¼ ln2/koff Kd ¼ koff/kon (M)
Acr-16TC/LNA 37 7.0 3.3 · 10
3(r
2 ¼ 0.98) 2.5 · 10
 5 (±7 · 10
 6) 2.8 · 10
5 8.4 · 10
 9
16TC/LNA 37 7.0 0.9 · 10
3 (r
2 ¼ 0.99) 1.5 · 10
 3 (±2.5 · 10
 4) 4.6 · 10
2 1.7 · 10
 6
9TC/LNA 37 7.0 2.0 · 10
3 (r
2 ¼ 0.985) 1.5 · 10
 3 (±4 · 10
 4) 4.6 · 10
2 7.2 · 10
 7
16TC/LNA 37 6.5 1.3 · 10
3 (r
2 ¼ 0.99) 1.6 · 10
 4 (±2 · 10
 6) 4.6 · 10
3 1.2 · 10
 7
9TC/LNA 37 6.5 2.5 · 10
3 (r
2 ¼ 0.98) 1.1 · 10
 3 (±4 · 10
 5) 6.3 · 10
2 4.4 · 10
 7
The half-life (t) of triplex was also reported. Correlation coefficients (r
2) are reported.
Thedatawereobtainedinabuffercontaining10mMcacodylate,150mMsodiumchloride,10mMMgCl2,P200.0005%(BufferH).Specificconditionsareindicated.
Figure 3. SPR experiments. Values of ln(kon),  ln(koff) (association and dis-
sociationrateconstants)and ln(Kd)(equilibriumdissociationconstant)forthe
different triplexes formed with (T,C)-containing TFO/LNAs. These values
were obtained at 37 C in a buffer containing 10 mM cacodylate, 150 mM
sodium chloride, 10 mM MgCl2, P20 0.0005%.
Figure 4. pH variations of melting temperatures [Tm ( C)] of the different
(T,C)-containing TFOswith the PPT duplextarget. Meltingtemperatures were
obtained in a buffer containing 10 mM cacodylate, 150 mM sodium chloride
and 10 mM MgCl2.
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increased, as expected for C-containing TFOs, ascribed to
the loss of cytosine protonation. As described in Figure 4,
the pH-dependence seemed to be equivalent for triplexes
formed with 16TC/LNAs compared to the ones formed
with the unmodiﬁed 16TC/po [as measured by the slope of
the graph Tm ¼ f(pH)]. Noteworthy no binding was detected
(Tm < 10 C) with the 16TC/po above pH 6.5 whereas the
16TC/LNA was strongly bound at pH 7 (Tm ¼ 47 C).
To obtain information concerning the binding of the 30
C-rich portion (CCCCCCT-30) in the 16TC sequence the sta-
bilities of different triplexes were measured. First the binding
to the PPT duplex of the 16TC/LNA was compared with that
of the 9TC/LNA (Tm values in Table 1). The deletion of the six
contiguous cytosines in the 9TC sequence induced a decrease
in triplex stability below pH 7, this decrease being stronger at
lower pH values [DTm(16TC/LNA-9TC/LNA) ¼ 1, 5 and 9 C
at pH 7, 6.5 and 6, respectively], consistent with the different
cytosine content of the TFOs (one in 9TC and seven in 16TC).
Second, we evaluated the binding of the 16TC/LNA to
the mutated PPT duplex containing the two mutations
(AGGAGGA-30, mutations in bold) in the region recognized
by the 30-end of the 16TC (CCCCCCT-30). The selective
recognition of the two targets by the 16TC/LNA increased
when pH decreased [DTm(PPT-mutPPT; 16TC/LNA) ¼ 3
and 9 C at pH 7 and 6.5, respectively].
This set of results are consistent with the fact that at neutral
pH, triplex stability with the 16TC/LNA was mainly driven
by the binding of the 50 T-rich portion (50-tTtTcTtTt) that
corresponds to the 9TC/LNA sequence. The binding of the
30 C-rich portion increased as the pH was decreased, favoring
the protonation of the cytosine segment.
To further understand the pH-dependence of triplex forma-
tion with pyrimidine TFO/LNAs. The 16TC/LNA and 9TC/
LNA were studied at pH 7 and 6.5 (Table 2). Changes in pH
values from 6.5 to 7 affected the stability of the triplex formed
with 16TC/LNA (14-fold increaseinKd/+0.5 unitof pH) more
than that of the one formed with 9TC/LNA (1.6-fold increase
in Kd/+ 0.5 unit of pH), supporting the results obtained by UV
Tm measurements and consistent with the different cytosine
composition, position and distribution (one internal in 9TC
and, six terminal and adjacent in 16TC) (28). From a kinetic
point of view, Kd variations as the pH was increased from
6.5 to 7, appeared to be mainly driven by koff, leading to faster
dissociations. The association was marginally affected by pH
variation for both 9TC/LNA and 16TC/LNA. However, what-
ever the pH value (7 or 6.5), the 9TC/LNA did associate
signiﬁcantly faster ( 2-fold) compared to the 16TC/LNA,
as expected for a shorter TFO.
Pyrimidine TFO/LNAs are efficient to interfere
with DNA acting proteins in vitro
To further characterize the DNA binding of (T,C)-containing
TFO/LNA, we evaluated the capacity of the corresponding
triplexes to interfere with DNA acting proteins, i.e. either a
restriction enzyme or an RNA polymerase.
First we exploited the fact that a Dra I cleavage site
(TTT#AAA) is present at the 50 side of the PPT oligopurine
strand and overlaps the PPT target on 3 bp. When triplex
formation occurred, Dra I cleavage was impaired only on
the site overlapping the PPT sequence. The TFO concentra-
tions for 50% of Dra I cleavage inhibition (IC50) were deter-
mined (Supplementary Figure S3):  250 nM for the 16TC/
LNA and  25 nM for the Acr-16TC/LNA, with a complete
inhibition at 100–200 nM. Under the same conditions
the isosequential phosphodiester TFOs (16TC/po and Acr-
16TC/po) did not inhibit cleavage at 37 C up to a concentra-
tion of 10 mM.
Second, the pyrimidine TFO/LNAs were evaluated for their
ability to interfere in vitro with an RNA polymerase moving
alongthe DNA.To address this point, a plasmid containing the
T7 polymerase promoter upstream the PPT site was used as
template for transcription assays (Figure 5). As shown on the
gel, templates harboring some of the triple-helical complexes
directed the synthesis of a truncated transcript of  330 nt.
Thus Acr-16TC/LNA was able to inhibit RNA synthesis more
efﬁciently than the unconjugated 16TC/LNA:  50% of trun-
cated transcripts were observed at 0.05 mM of Acr-16TC/LNA
compared to 1 mM of 16TC/LNA. Under these transcription
conditions the phosphodiester TFOs (16TC/po and Acr-16TC/
po) were unable to inhibit transcription (upto 10 mM).
The speciﬁcity of transcription inhibition was established
according toseveral experiments.First,noeffect wasobserved
with another pyrimidine LNA oligonucleotide (16py(1)/LNA,
sequence in Figure 1). Second, to demonstrate a triplex-
mediated inhibition of transcription, the site of transcription
arrest obtained in the presence of TFO, was compared to a run-
off transcription product using the template plasmid digested
by Dra I; this restriction enzyme cleaves exactly at the 50
boundary of the PPT oligopurine sequence (lane M,
Figure 5B).
Finally, SP6 RNA polymerase was used to initiate transcrip-
tion in the opposite direction as compared to the T7 RNA
polymerase (Figure 5A). SP6 transcription in the presence
of pyrimidine TFO/LNAs also produced a truncated product
that corresponded to an arrest of RNA synthesis at the PPT
site, localized by the Dra I marker as described above (data not
shown), and the TFO-acridine conjugate was still more effec-
tive than the unconjugated TFO at arresting elongating SP6
RNA polymerase. These results support a physical blockage of
the RNA polymerase by the TFO/LNAs, whatever the triplex
side encountered by the polymerase, the 50 side of the PPT
oligopurine sequence corresponding to the acridine intercala-
tion site at the duplex–triplex junction (during T7 transcrip-
tion) or the opposite one (during SP6 transcription).
These data on two different DNA-associated biological
activities of pyrimidine TFO/LNA were consistent with
physico-chemical data from UV spectroscopy and gel shift
analyses described above: strong and still speciﬁc binding
to PPT DNA target, increase in stability induced by interca-
lator conjugation (as measured here by 10/20-fold decrease
in inhibitory concentrations) and ﬁnally, higher stability of
triplexes formed with TFO/LNA compared to TFO/po.
Triplex-based activity in cells mediated by pyrimidine
TFO/LNAs at submicromolar concentrations
To date, pyrimidine TFO/LNAs have not been tested in cells.
The in vitro properties described above, especially those of the
conjugated TFO, Acr-16TC/LNA, would seem consistent with
activity in cell-based assays. Cellular activities of pyrimidine
Nucleic Acids Research, 2005, Vol. 33, No. 13 4229TFO/LNAs were estimated in a transient expression system
that was designed for quantitative and fast evaluation of mole-
cules targeted against the oligopyrimidine oligopurine PPT
sequence and for demonstration of a triplex-based mechanism.
Indeed two different DNA templates [(+)PPT/luc and
(+)mutPPT/luc plasmids] coding for the ﬁreﬂy luciferase
and containing the wild-type PPT sequence or the mutated
sequence (mutPPT with two mutations, Figure 1) were
used. The PPT or the mutPPT sequence was located in the
transcribed but untranslated region of luc gene (Figure 6A).
HeLa cells were transiently transfected with the (+)PPT/luc
plasmid [or the (+)mutPPT/luc plasmid] together with the
pRL-TK plasmid (expressing Renilla luciferase and used
for correction of transfection efﬁciency) and with various
TFOs. Two transfection mixtures were prepared for plasmids
and TFO, respectively, in order to prevent direct interaction
between TFO and DNA template before transfection; the two
mixtures were added to cell cultures simultaneously. The
modulation of ﬁreﬂy luciferase expression and messenger
RNA (mRNA)levels induced by TFOtreatment was evaluated
24 h after treatment. The activities of different pyrimidine
TFO/LNAs (sequences in Figure 1) were determined and
results are reported in Figure 6.
Acr-16TC/LNA did induce an inhibition of ﬁreﬂy luciferase
expression, with 50% inhibition at  50–100 nM. To establish
triplex involvement in the observed inhibition several criteria
were examined. First, a control LNA oligonucleotide-acridine
conjugate was used, presenting the same base composition as
the 16TC/LNA and with an acridine unit at its 50-end
(Acr-16py(2)/LNA): after treatment with this oligonucleotide
no decrease in luciferase activity was detected in conditions
where the speciﬁc Acr-16TC/LNA-induced 75% luciferase
inhibition. Second the (+)mutPPT/luc plasmid was treated
with the Acr-16TC/LNA: the presence of two mutations in
the PPT target sequence abolished the inhibitory effect of
Acr-16TC/LNA. Third ﬁreﬂy luciferase mRNAs were quan-
tiﬁed: in the presence of Acr-16TC/LNA a reduction of
luciferase RNA levels did occur (Figure 6C), together with
the decrease in luciferase protein. This excluded that the TFO/
LNA could act by binding to the oligopurine sequence present
on the mRNA produced from the (+)PPT/luc DNA. Indeed the
used TFO/LNAs (with alternating LNA and DNA along the
Figure5.InvitroarrestofRNAsynthesisby(T,C)-containingTFO/LNAs.(A)Descriptionofthetranscriptionsystem.ThepSP-F47plasmidcontainsthePPTtarget
between two bacteriophage promoters (T7 and SP6). Full-length transcripts (660 or 597 nt long, respectively.) correspond to transcription of the BspE I or Bsu36 I
(resp.)linearizedpSP-F47plasmid;thePPTsequenceispositioned(330or540nt,respectively),downstreamofthetranscriptioninitiationsite;truncatedtranscripts
are compared to transcripts of Dra I-linearized pSP-F47 plasmid, used as size markers (Dra I RNA marker; lane (M) in Figure 5B). (B) In vitro transcription assay.
BspE I-linearized plasmid was incubated in the absence or in the presence of different concentrations of TFO/LNAs and used as template for T7 transcription. The
transcription products (full-length and truncated) were analysed by electrophoresis on a 6% polyacrylamide sequencing gel. Lane (M): Dra I RNA marker.
Quantification of transcription inhibition measured by the percentage of truncated transcripts (corrected by transcript lengths) is reported below the gel.
4230 Nucleic Acids Research, 2005, Vol. 33, No. 13sequence) were unable to induce RNase H activation in vitro
when bound to the PPT RNA sequence (data not shown), as
expected from previous work (29). This set of data demon-
strated that the TFO-induced activity was caused by complex
formation on the PPT sequence, leading to transcriptional
inhibition at the DNA level. Noteworthy triplex formation
likely occured intracellularly in our experimental conditions.
Indeed, the same level of luciferase inhibition was induced by
the Acr-16TC/LNA when the TFO and DNA template were
introduced within the cells simultaneously (as previously
described) or sequentially (ﬁrst, TFO and 24 h later, DNA;
Materials and Methods; Supplementary Figure S4).
The efﬁcacy of triplex-induced inhibition was studied by
using various pyrimidine TFOs. The unconjugated 16TC/LNA
was much less active than the Acr-16TC/LNA, with >20-fold
increase in the IC50 ( 30% inhibition at 2 mM); equivalent
activity was obtained with 16TC/LNA and 16TC/LNA (dif-
fering by the presence of methylated or unmodiﬁed DNA
cytosines), consistent with the thermal stability data. To evalu-
ate the activity of another TFO-intercalator conjugate com-
monly used in triplex-based applications, the 50-end of the
16TC/LNA was linked to a psoralen derivative (Pso-16TC/
LNA). As with the acridine, the psoralen moiety should inter-
calate at the duplex–triplex junction and thus increase the
stability of the non-covalent triplex in the absence of photoac-
tivation, as already described for other TFO chemistries
(18,30). The psoralen-conjugated TFO was more active in
cells than the unconjugated 16TC/LNA and signiﬁcantly
less efﬁcient than the isosequential acridine conjugate (50%
inhibition at 1 mM for the Pso-16TC/LNA compared to >2 mM
for the 16TC/LNA and 50–100 nM for the Acr-16TC/LNA).
For all tested TFOs triplex involvement was supported by the
absence of luciferase inhibition in the (+)mutPPT system.
Finally, under the same conditions, no activity was observed
for the phosphodiester Acr-16TC/po.
These data support the high potency of pyrimidine TFO/
LNAs attached to DNA intercalating agents, in contrast to
phophodiester pyrimidine TFOs, fortriplex-based applications
in cells.
DISCUSSION
In the present work we have characterized the binding
properties and cellular activities of triplexes formed with
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Figure 6. Cellularactivityof(T,C)-containingTFO/LNAs:inhibitionoftranscriptionelongation.(A)Experimentaldesign.Schematicrepresentationofthe(+)PPT/
luc or (+)mutPPT/luc plasmids. These plasmids allow expression of the firefly luciferase reporter gene (luc) (Materials and Methods). The PPT (or the mutPPT 50,
AAAAGAAAAAGGAGGA-30, two mutations in bold) sequence was inserted just upstream the luc gene. (B) The expression vector, (+)PPT/luc or (+)mutPPT/luc
plasmid, was introduced with the pRL-TK plasmid, in the presence or absence of (T,C)-containing TFO/LNAs. Plasmids and TFOs were introduced independently
using two transfection mixtures that were added to the cells at the same time. Cell extracts were analysed for firefly and Renilla luciferases activities, 24 h after
transfection bya cationicdendrimer (Superfect).Normalizedfirefly/RenillaluminescenceintensityratiosarereportedfordifferentTFO/LNAconcentrations.Data
arederivedfromatleastfourexperiments.Acr-16TC/po
$ ¼ Acr-16TC/po,30-modifiedbyincorporationofapropylaminegroup.(C)Ratioof(Firefly/Renilla)RNA
levelswasdeducedfromcompetitiveRT–PCR(MaterialsandMethods):decreaseofRNAlevelwascomparedwiththatobtainedfortransfectionof(+)PPT/lucand
RL-TK plasmids in absence of TFO/LNAs.
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attached or not to an intercalating agent (Acr-16TC/LNA
and 16TC/LNA, respectively) with the aim to determine the
speciﬁc inﬂuence of intercalator conjugation in the context of
pyrimidine TFO/LNAs. We showed that the TFO/LNAs are
reliably active intracellularly at levels that might permit
experimentation on a variety of interesting issues and we
have attempted to understand the biophysical parameters
that underlie TFO/LNA bioactivity.
Our in vitro data (obtained at 37 C and neutral pH) showed
a strong DNA binding of Acr-16TC/LNA with a dissociation
equilibrium constant (Kd)o f 10 nM, 200-fold lower than for
the unconjugated 16TC/LNA. Such high afﬁnity is not detri-
mental for speciﬁcity, since binding strongly decreases when
mutations are present in the DNA target. These data concern-
ing acridine-induced triplex stabilization extend the results
obtained with other TFO chemistries to TFO/LNAs; notewor-
thy the use of LNA modiﬁcations is associated with tight
binding of pyrimidine and C-rich TFOs (16TC sequence) in
conditions simulating physiological ones. Here we have
proceeded towards an understanding of the origins of triplex
stabilization observed with the conjugated compared to the
unconjugated TFO. To address this question we performed
kinetic analyses. We demonstrated that triplex stabilization
induced by acridine conjugation was mainly due to a decrease
in the dissociation rate constant, with residence time in
the range of 10 h; the association rates were also slightly
more favorable, with a 3-fold increase. The origins of the
increased association rate might be attributed to protonation
of the aminoacridine unit inducing favorable electrostatic
interactions. The decreased dissociation rate is consistent
with intercalation of the acridine moiety at the duplex–
triplex junction, that is a 50-YpR-30 sequence known to be
particularly appropriate.
This high triplex stability observed for the studied pyrimi-
dineTFO/LNAstranslates intobiologicalactivities.Weevalu-
ated the in vitro and cellular activities of TFO/LNAs using
experimental systems designed to demonstrate quantitatively
and rapidly atriplex-based mechanism.Theircapacitytointer-
fere with transcription elongation was estimated. We could
demonstrate the triplex involvement in transcription arrest,
both in vitro and in cells: in vitro RNA synthesis was halted
atthetriplexsitewheretheTFOwasformed;incells,thetrans-
criptionofthetargetgenewasinhibitedwhereastheexpression
ofthe gene containing a mutated versionof the target sequence
(mutPPT DNA with two mutations) was not affected. Our data
also showed that both LNA modiﬁcations and intercalator
attachment did increase TFO activity without affecting its
sequence-speciﬁcity, consistent with binding data obtained
in vitro. In addition to the acridine derivative we tested another
commonly used intercalating agent, the psoralen; its mode of
intercalation is close to that of acridine, with binding parallel
to the base pairs. Psoralen conjugation (in Pso-16TC/LNA)
also induced an increase in activity but to a lesser extent
compared to the acridine [IC50(Pso-16TC/LNA)  1 mM com-
pared to IC50(Acr-16TC/LNA)  0.1 mM]. Such difference
might be due to the formation of a slightly less stable triplex
(data not shown) and more likely to different intracellular
transfer of the two conjugates. Indeed conjugation of acridine
was demonstrated to improve delivery whenthe conjugate was
transfected with cationic reagents (31).
Concerning efﬁciency, the activity of acridine-conjugated
16TC/LNA was observed at relatively low TFO concentra-
tions (IC50 0.1 mM). Generally pyrimidine TFOs and espe-
cially C-rich sequences are described to be poorly active in
cells and G-containing TFOs [(T,G)- and (A,G)-motifs] have
therefore mainly been used [for a review in (2)]. The latter
have also been attached to intercalating agents (psoralen,
daunomycin, acridine) and have been used successfully either
to induce targeted mutagenesis or to inhibit transcription
(15,17,18). In all cases they have exhibited inhibitory activity
in the micromolar range ( 0.5–1 mM, 24 h after treatment)
when administrated with cationic agents. To our knowledge,
cellular activities of non-covalent pyrimidine triplexes were
not previously reported however, in two systems (19,32)
pyrimidine psoralen-linked TFOs were described to be active
when photoactivation was performed to induce a targeted
DNA cross-link. In one case, a 15mer phosphodiester TFO
directed against the IL2-Ra promoter was able to partially
prevent transcription factor binding and then to inhibit tran-
scription initiation, when preincubated in vitro with the target
plasmid and electroporated (at 20 mM in the electroporation
mixture). In the second case, a T-rich TFO containing 20-
modiﬁed sugars directed against the HPRT gene was able
to cross-link the target locus (at 5 mM in the electroporation
mixture) and mutations were induced at the triplex site, due
to triplex processing by the repair machinery. Of course com-
parison of TFO efﬁciency in different experimental settings
(TFO sequence, target gene, cell type, delivery methods)
for different types of activities (inhibition of transcription
(initiation or elongation) or induction of mutations) is difﬁcult,
but high efﬁciency of Acr-16TC/LNA was observed here,
supporting the potential of pyrimidine TFO/LNA for triplex-
based applications in cells with efﬁcient targeting of chromo-
somally located genes under conditions where TFO/LNAs
were highly active, the parent phosphodiester oligonucleotides
did not exhibit any inhibitory effect. Noteworthy our experi-
mental system is quite unfavorable: indeed, the target
sequence was relatively short (16 bp) including six contiguous
(CG bp), and the cellular activity to inhibit was transcription
elongation, known to be difﬁcult to arrest. TFO/LNAs might
likely be active at still lower concentrations in another
context when interference with other biological activities is
envisioned.
Finally the use of pyrimidine TFOs versus G-containing
ones presents some advantages, e.g. a lower tendency to
self-associate under physiological conditions and a lower
ability to bind cellular proteins, a phenomenon competing
with triplex formation and potentially leading to unexpected
cellular effects, and the potency to target all oligopyrimidi-
ne·oligopurine sequences, due to a perfect isomorphism
between the T·AxT and C·GxC+ base triplets. However the
major disadvantage is their pH-dependent binding to DNA
which generally makes the corresponding triplex unstable at
neutral pH. In this work we explored the pH-dependence of
triplexes formed with pyrimidine TFO/LNAs. Kinetically the
major effect did concern the dissociation process, as already
reported for non-modiﬁed triplexes (24): a pH increase was
associated with a faster dissociation.However with Acr-16TC/
LNA a stable triplex was still formed at neutral pH under
conditions closely mimicking physiological ones and cellular
activity was realised. It is likely that pyrimidine TFO/LNA
4232 Nucleic Acids Research, 2005, Vol. 33, No. 13attachedtoother intercalatorswith the samebinding mode will
have similar properties, as illustrated here with the TFO/
LNA-psoralen conjugate.
Targeted gene knock-down is possible with different pow-
erful techniques, including antisense and siRNA approaches.
However among oligonucleotide-based technologies, TFOs
offer unique potential since, as DNA binding molecules
that recognize speciﬁc sequences, they can be used to under-
stand DNA-occuring processes and the associated biological
functions. In this context TFO can also be useful as DNA
recognition elements for the positioning of DNA interacting
orreactive compounds,suchasanticancerdrugs (33),based on
chemical conjugation of these agents with TFO (34,35).
Manipulation of chromatin structure is another promising
application of TFOs (36,37). These two latter aspects have
been successfully explored in vitro. For further triplex-based
cellular experiments it is still necessary to identify novel TFO
chemistries, associated with increased activities, that are easy
to synthetize and compatible with conjugation synthesis. The
LNA-modiﬁed pyrimidine oligonucleotides described
here fulﬁll these criteria. Our work is the initial step for
their use in future developments of innovative antigene
applications.
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Supplementary Material is available at NAR Online.
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